BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioMarin Pharmaceutical Inc (BMRN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as FDA approvals and revenue growth, the financial performance, insider selling, and technical indicators suggest caution. The stock lacks clear upward momentum, and there are competitive headwinds for its key products. A hold strategy is recommended until more favorable entry points or stronger signals emerge.
The MACD is negative and contracting (-0.303), RSI is neutral at 49.357, and moving averages are converging, indicating no clear trend. The stock is trading near support levels (S1: 59.061), but lacks bullish momentum.
FDA approval of PALYNZIQ for adolescents with PKU.
Revenue growth of 17.03% YoY in Q4
Analyst price target increases from Barclays, Canaccord, and others, with targets as high as $105.
Insider selling increased by 1502.12% over the last month.
Net income dropped by -137.28% YoY, with EPS also down -137.50%.
Competitive headwinds for Voxzogo and potential challenges from new therapies.
Weak technical indicators and lack of clear momentum.
In Q4 2025, revenue increased by 17.03% YoY to $874.57M, but net income dropped to -$46.57M (-137.28% YoY) and EPS fell to -$0.24 (-137.50% YoY). Gross margin improved slightly to 81.55%.
Analysts are generally positive, with multiple firms raising price targets (e.g., Barclays to $105, Canaccord to $104). However, there are concerns about competitive headwinds and soft guidance for Voxzogo sales.
